Indian stocks: Visit www.stage2stocks.com →

Cognition Therapeutics, Inc.

Stage 4 · Declining · week 14

As of Oct 22, 2026, Cognition Therapeutics is in Stage 4, the downtrend phase, now in week 14 (since Jul 20, 2026). It closed at $0.70, 61.1% below its 52-week high and below its 200-day average, which is falling.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disord… More about the company

$0.70
-7.76% today
$66.6M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CGTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S4 20w
S4 17w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 1w → S4 16w → S1 6w → S2 9w → S3 7w → S2 7w → S3 4w → S4 20w → S1 11w → S4 17w → S1 4w → S2 13w → S3 5w → S2 2w → S3 9w → S4 9w → S1 11w → S4 14w current
Total tracked: 165 weeks across 18 stage runs.

CGTX among Biotechnology397th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…397CGTXStage 4 · wk 1418−26.2%
vs 52W High
-61.1%
$0.60 lo$1.80 hi
61.1% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 14
1w13w26w
Week 14, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-35.6%
200 DMA: $1.09 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
2.08x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-26.2%
3M
-23.8%
6M
-44.4%
YTD
-52.3%
1Y
-60.4%
Scan Membership
Breakout Watch
Latest: 2024-05-23
4 appearances in last 60 days. First seen: 2023-01-25.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 14 · Vol 2.08x
2026-10-21S4
Wk 14 · Vol 0.59x
2026-10-20S4
Wk 14 · Vol 0.90x
2026-10-19S4
Wk 13 · Vol 1.12x
2026-10-16S4
Wk 13 · Vol 0.82x
2026-10-15S4
Wk 13 · Vol 1.31x
2026-10-14S4
Wk 13 · Vol 0.98x
2026-10-13S4
Wk 13 · Vol 8.14x
2026-10-12S4
Wk 12 · Vol 0.90x
2026-10-09S4
Wk 12 · Vol 0.69x
2026-10-08S4
Wk 12 · Vol 0.99x
2026-10-07S4
Wk 12 · Vol 0.43x
Moving averages & range
50 DMA
$0.95
200 DMA
$1.09
52W High
$1.80
52W Low
$0.60
5D Low
$0.70
Resistance levels (recent highs)
20d High
$0.96
60d High
$1.13
120d High
$1.68
250d High
$1.80
Next resistance
+36.9%
to 20d High
ROE
-83.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 2.0

Cognition Therapeutics: quick answers

What stage is Cognition Therapeutics in?

As of Oct 22, 2026, Cognition Therapeutics (CGTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 20, 2026 and is in week 14. What the four stages mean

Is Cognition Therapeutics in an uptrend?

No. Cognition Therapeutics is in a Stage 4 downtrend. It trades 35.6% below its 200-day average, which is falling.

How far is Cognition Therapeutics from its 52-week high?

Cognition Therapeutics closed at $0.70 on Oct 22, 2026, 61.1% below its 52-week high of $1.80. Its 52-week low is $0.60.

How has Cognition Therapeutics performed over the past year?

As of Oct 22, 2026, Cognition Therapeutics is down 60.4% over the past year and down 52.3% so far in 2026.

Which sector and industry is Cognition Therapeutics in?

Cognition Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.